|
|
|
|
||
Re: SHPGY going after BMRN ...maybe it is only me. But Shire appears to be much more interested in advancing M & A sourced drugs over licensed indications. Even though the market for Hemo ERT from SGMO is a HUGE improvement over other ERT methods. What can Edward do? What can we do? To move any IND forward. "B" Seems that SGMO is about the last biotech to license T-cell products. |
return to message board, top of board |